2 - TI Pharma
2 - TI Pharma 2 - TI Pharma
Chapter 12 Angiopoietine-like protein 4 is differentially regulated by 231 glucocorticoids and insulin in vitro and in vivo in healthy humans. Part IV Metabolic effects of glucocorticoids and interaction with systemic inflammation Chapter 13 Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: diabetogenic effects and inflammation reduction on the balance. 249 Chapter 14 Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. 267 Part V Discussion Chapter 15 Diabetogenic effects of glucocorticoid drugs: the knowns and the unknowns 289 Nederlandse samenvatting (Dutch summary) 329 Dankwoord (Acknowledgements) 339 Biography 347 List of Publications 351 List of co-author affiliations 357 Color Figures 365
- Page 2: Diabetogenic Effects of Glucocortic
- Page 6: VRIjE UNIVERSITEIT Diabetogenic Eff
- Page 10: Leescommissie: prof.dr. M. Boers pr
- Page 18: PART Introduction I
- Page 24: Chapter 1 General Introduction The
- Page 28: Chapter 1 General Introduction and
- Page 32: Chapter 1 General Introduction The
- Page 36: Chapter 1 General Introduction REFE
- Page 40: Chapter 1 General Introduction 32.
- Page 48: Chapter 2 Glucocorticoids: metaboli
- Page 52: Chapter 2 Glucocorticoids: metaboli
- Page 56: Chapter 2 Glucocorticoids: metaboli
- Page 60: Chapter 2 Glucocorticoids: metaboli
Chapter 12 Angiopoietine-like protein 4 is differentially regulated by 231<br />
glucocorticoids and insulin in vitro and in vivo in healthy<br />
humans.<br />
Part IV Metabolic effects of glucocorticoids and interaction with<br />
systemic inflammation<br />
Chapter 13 Metabolic effects of high-dose prednisolone treatment in early<br />
rheumatoid arthritis: diabetogenic effects and inflammation<br />
reduction on the balance.<br />
249<br />
Chapter 14 Glucose tolerance, insulin sensitivity and beta-cell function<br />
in patients with rheumatoid arthritis treated with or without<br />
low-to-medium dose glucocorticoids.<br />
267<br />
Part V Discussion<br />
Chapter 15 Diabetogenic effects of glucocorticoid drugs: the knowns<br />
and the unknowns<br />
289<br />
Nederlandse samenvatting (Dutch summary) 329<br />
Dankwoord (Acknowledgements) 339<br />
Biography 347<br />
List of Publications 351<br />
List of co-author affiliations 357<br />
Color Figures 365
Change language